Personalized melanoma vaccine trial succeeds

Moffitt Cancer Center is testing a promising personalized mRNA vaccine for melanoma. Unlike standard vaccines, this immunotherapy is tailored to a patient's specific tumor mutations to train the immune system to destroy residual cancer cells, significantly reducing the risk of recurrence and potentially offering a safer alternative to traditional immunotherapies.